Business Description
Biotricity Inc
NAICS : 334510
SIC : 3841
ISIN : US09074H2031
Total Employee Number:
46Description
Biotricity Inc is a medical technology company focused on biometric data monitoring solutions. Its objective is to deliver remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Its approach the diagnostic side of remote patient monitoring by applying innovation within existing business models where reimbursement is established. The company is developed its Bioflux COM technology, which has received clearance from the U.S. Food and Drug Administration (FDA), comprised of a monitoring device and software components. It is a technology company focused on earning utilization-based recurring technology. The company operates in one operating segment.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.02 | |||||
Equity-to-Asset | -5.59 | |||||
Debt-to-Equity | -0.8 | |||||
Debt-to-EBITDA | 18.37 | |||||
Interest Coverage | 0.38 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | -36.15 | |||||
Beneish M-Score | -4.44 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -19.3 | |||||
3-Year FCF Growth Rate | 74.5 | |||||
3-Year Book Growth Rate | 19 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.49 | |||||
9-Day RSI | 40.24 | |||||
14-Day RSI | 43.34 | |||||
3-1 Month Momentum % | -3.68 | |||||
6-1 Month Momentum % | -57.89 | |||||
12-1 Month Momentum % | -79.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.15 | |||||
Quick Ratio | 0.11 | |||||
Cash Ratio | 0.01 | |||||
Days Inventory | 210.84 | |||||
Days Sales Outstanding | 48.37 | |||||
Days Payable | 557.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -48.7 | |||||
Shareholder Yield % | -63.27 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 81.47 | |||||
Operating Margin % | 9.56 | |||||
Net Margin % | -16.41 | |||||
EBITDA Margin % | 8.94 | |||||
FCF Margin % | 0.99 | |||||
OCF Margin % | 0.99 | |||||
ROA % | -44.09 | |||||
ROIC % | 7.49 | |||||
3-Year ROIIC % | 81.89 | |||||
ROC (Joel Greenblatt) % | 311.12 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.16 | |||||
Price-to-Free-Cash-Flow | 10.35 | |||||
Price-to-Operating-Cash-Flow | 10.35 | |||||
EV-to-EBIT | 22.37 | |||||
EV-to-EBITDA | 22.3 | |||||
EV-to-Revenue | 1.99 | |||||
EV-to-Forward-Revenue | 2.41 | |||||
EV-to-FCF | 201.78 | |||||
Price-to-GF-Value | 0.28 | |||||
Earnings Yield (Greenblatt) % | 4.47 | |||||
FCF Yield % | 7.8 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:BTCY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Biotricity Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 16.402 | ||
| EPS (TTM) ($) | -0.133 | ||
| Beta | -0.134 | ||
| 3-Year Sharpe Ratio | -0.55 | ||
| 3-Year Sortino Ratio | -0.76 | ||
| Volatility % | 57.34 | ||
| 14-Day RSI | 43.34 | ||
| 14-Day ATR ($) | 0.013429 | ||
| 20-Day SMA ($) | 0.114588 | ||
| 12-1 Month Momentum % | -79.63 | ||
| 52-Week Range ($) | 0.0879 - 0.7536 | ||
| Shares Outstanding (Mil) | 20.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biotricity Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biotricity Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2027 | 2027-02-11 16:30 | In 163 days | ||
| Third quarter earnings results for 2027 | 2027-02-11 | In 162 days | ||
| Second quarter earnings conference call for 2027 | 2026-11-13 16:30 | In 73 days | ||
| Second quarter earnings results for 2027 | 2026-11-13 | In 72 days | ||
| General meeting for 2026 | 2026-09-04 | In 2 days | ||
| First quarter earnings results for 2027 | 2026-08-19 | 0.12 (+9.10%) | ||
| Annual report for 2026 | 2026-07-14 | 0.12 (+1.56%) | ||
| Q2 Virtual Investor Summit | 2026-06-24 11:00 | 0.12 (+2.63%) | ||
| LD Micro Invitational XVI | 2026-05-18 12:30 | 0.19 (-2.83%) | ||
| Third quarter earnings conference call for 2026 | 2026-02-11 16:30 | 0.29 (+7.89%) |
Show
Entries
Biotricity Inc Frequently Asked Questions
What is Biotricity Inc(BTCY)'s stock price today?
The current price of BTCY is $0.10. The 52 week high of BTCY is $0.75 and 52 week low is $0.09.
When is next earnings date of Biotricity Inc(BTCY)?
The next earnings date of Biotricity Inc(BTCY) is 2026-11-13 Est..
Does Biotricity Inc(BTCY) pay dividends? If so, how much?
Biotricity Inc(BTCY) does not pay dividend.
Guru Commentaries on OTCPK:BTCY
Rogue Funds
Bullish
2025 Q1
What the manager wrote
Biotricity manufactures and sells a three-lead heart monitor that helps predict heart-related issues, boasting a 99% retention rate. The company has grown at over 25% to $13mm in revenue, with expectations for further increases. They are transitioning to an AI-focused model, which initially slowed sales but is now leading to numerous pilot studies. This shift is expected to significantly expand gross margins. The company is projected to reach $25mm-$30mm in ARR with $6mm+ in FCF within a year, despite a high debt load. The upcoming pilot studies are crucial for rapid revenue growth, potentially leading to a valuation of 8x revenue once consistent cash flow is demonstrated.
Press Release
Articles on Biotricity Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers